BioClinica to Release Fourth Quarter and Year-End 2012 Financial Results on February 6, 2013

  BioClinica to Release Fourth Quarter and Year-End 2012 Financial Results on
  February 6, 2013

Business Wire

NEWTOWN, Pa. -- February 4, 2013

BioClinica, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial
management solutions, will release its financial results for the fourth
quarter and year ended December 31, 2012 on Wednesday, February 6, 2013. As a
result of the transaction announced on January 30, 2013, management of
BioClinica, Inc. will not be hosting a conference call.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management solutions. BioClinica supports
pharmaceutical and medical device innovation with imaging core lab, internet
image transport, electronic data capture, interactive voice and web response,
clinical trial management and clinical supply chain design and optimization
solutions. BioClinica solutions maximize efficiency and manageability
throughout all phases of the clinical trial process. With over 20 years of
experience and more than 2,000 successful trials to date, BioClinica has
supported the clinical development of many new medicines from early phase
trials through final approval. BioClinica operates state-of-the-art,
regulatory-body-compliant imaging core labs on two continents, and supports
worldwide eClinical and data management services from offices in the United
States, Europe and Asia. For more information, please visit www.bioclinica.com

Important Information About the Tender Offer

This announcement and the description contained herein are for informational
purposes only and are not an offer to purchase or a solicitation of an offer
to sell securities of BioClinica, Inc. The tender offer described herein has
not yet been commenced. At the time the tender offer is commenced, affiliates
of JLL Partners intend to file a tender offer statement on a Schedule TO
containing an offer to purchase, a letter of transmittal and other related
documents with the Securities and Exchange Commission. At the time the tender
offer is commenced, BioClinica, Inc. intends to file with the Securities and
Exchange Commission a solicitation/recommendation statement on Schedule 14D-9
and, if required, will, file a proxy statement or information statement with
the Securities and Exchange Commission in connection with the merger, the
second step of the transaction, at a later date. Such documents will be mailed
to stockholders of record and will also be made available for distribution to
beneficial owners of common stock of BioClinica, Inc. The solicitation of
offers to buy common stock of BioClinica will only be made pursuant to the
offer to purchase, the letter of transmittal and related documents.
Stockholders are advised to read the offer to purchase and the letter of
transmittal, the solicitation/recommendation statement, the proxy statement,
the information statement and all related documents, if and when such
documents are filed and become available, as they will contain important
information about the tender offer and proposed merger. Stockholders can
obtain these documents when they are filed and become available free of charge
from the Securities and Exchange Commission's website at http://www.sec.gov,
or from the information agent JLL selects. In addition, copies of the
solicitation/recommendation statement, the proxy statement and other filings
containing information about BioClinica, Inc., the tender offer and the merger
may be obtained, if and when available, without charge, by directing a request
to BioClinica, Inc. Attention: Ted Kaminer, Chief Financial Officer, at 826
Newtown-Yardley Rd., Newtown, PA 18940, or on BioClinica’s corporate website
at http://www.bioclinica.com .

Forward-looking statements

Certain statements made in this press release are “forward-looking statements”
intended to qualify for the safe harbors from liability established by the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements may be identified by, among other things, the use of
forward-looking terminology such as “believes”, “expects”, “may”, “should” or
“anticipates” or the negative thereof or other variations thereon or
comparable terminology, or by discussions of strategy that involve risks and
uncertainties. Such forward-looking statements include the decision by
BioClinica, Inc. to enter into an agreement to be acquired by the holding
company controlled by JLL Partners, the ability of BioClinica, Inc. and the
holding company controlled by JLL Partners to complete the transaction
contemplated by the definitive agreement, including the parties’ ability to
satisfy the conditions set forth in the merger agreement, and the possibility
of any termination of the definitive agreement. The forward-looking statements
contained in this press release are based on our current expectations, and
those made at other times will be based on our expectations when the
statements are made. Factors that could cause or contribute to such
differences include, but are not limited to, the expected timetable for
completing the proposed transaction; the risk and uncertainty in connection
with a strategic alternative process; financial results; the demand for our
services and technologies; growing recognition for the use of independent
medical image review services; trends toward the outsourcing of imaging
services in clinical trials; realized return from our marketing efforts;
increased use of digital medical images in clinical trials; integration of our
acquired companies and businesses; expansion into new business segments; the
success of any potential acquisitions and the integration of current
acquisitions; and the level of our backlog are examples of such
forward-looking statements; the timing of revenues due to the variability in
size, scope and duration of projects; estimates made by management with
respect to our critical accounting policies; regulatory delays; clinical study
results which lead to reductions or cancellations of projects and other
factors, including general economic conditions and regulatory developments,
not within our control. Further information can be found in the risk factors
contained in the Annual Report of BioClinica, Inc. on Form 10-K for the year
ended December 31, 2011 and most recent filings. BioClinica, Inc. does not
undertake to update the disclosures made herein, and you are urged to read our
filings with the Securities and Exchange Commission.

                                     ####

Contact:

BioClinica, Inc.
Company
Ted Kaminer, 267-757-3097
or
Porter, LeVay & Rose, Inc.
Investors
Cheryl Schneider, 212-564-4700